HPV Vaccination in India: Overview and Challenges
The recent inclusion of the HPV vaccine Gardasil-4 in India's national immunisation programme, Mission Indradhanush, marks a significant public health intervention. This initiative is aimed at reducing cervical cancer, a leading cause of cancer deaths among Indian women, accounting for 1,20,000 cases and approximately 80,000 deaths annually.
Controversies and Public Debate
- The HPV vaccine has faced skepticism regarding its efficacy and safety.
- Concerns have been raised about its protection duration and potential increased cancer risk.
- Arguments against the vaccine have been supported by references to the book HPV Vaccine on Trial, which questions the vaccine's safety and commercial motivations behind its promotion.
- Rumors, such as claims of infertility caused by the vaccine, further fuel public apprehension.
Scientific Evidence
- Initial clinical trials had inadequate follow-up times to establish long-term efficacy.
- Recent studies, however, provide more substantial evidence of vaccine efficacy.
- The Swedish cohort study reported a 79% lower cervical cancer risk in women vaccinated before age 17.
- A review of 54 studies confirmed significant reductions in HPV infections and cervical cancer risk post-vaccination.
Public Trust and Safety Concerns
- The history of HPV vaccination in India is marred by past controversies, such as the 2009 trial deaths in Andhra Pradesh and Gujarat.
- Safety concerns often stem from the belief that regulatory approvals precede comprehensive safety data.
- Vaccine safety surveillance systems, such as the AEFI in India, aim to mitigate these concerns but are often underutilized.
Policy Decisions and International Influence
- Despite having an indigenous vaccine, India's programme currently uses the foreign-produced Gardasil-4.
- The Indian Council of Medical Research is evaluating the efficacy of the domestic vaccine Cervavac.
- International support, such as GAVI's $250-million grant, underscores the global priority to combat cervical cancer.
Conclusion
India's decision to implement HPV vaccination reflects a complex interplay of scientific evidence, policy considerations, and public trust. The programme's success will hinge on transparent implementation, effective communication, and gaining public confidence. Preventing cervical cancer requires more than vaccination; it necessitates sustained public trust and engagement.
